Corixa to exploit new solid tumour marker:
This article was originally published in Clinica
Corixa has obtained worldwide rights to diagnostic use of the tumour marker Her-2/neu. The protein was patented this month by the University of Washington in the US. Seattle-based Corixa is to develop vaccines based on Her-2/neu, as well as antibody assays for early detection of solid tumours.